Dare Bioscience (DARE)
(Real Time Quote from BATS)
$0.40 USD
-0.04 (-8.26%)
Updated May 28, 2024 12:26 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 81 - 100 ( 212 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts NDA for DARE-BV1, and Sets PDUFA Date for December 7th
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NICHD Collaboration for Ovaprene Phase 3 Expected to Provide Key Infrastructure and Cost Savings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
New CRADA Agreement Should Offset Costs of Ovaprene Pivotal Phase 3 Study
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Announces Another Milestone in Busy Summer with Receipt of Gates Foundation Grant to Develop LARC1
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Gates Foundation Grants Upto $49M for DARE-LARC1-Total Commitment ~$70M
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Hits Major Milestone with Submission of NDA for BV1; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submitted for DARE-BV1, Potential PDUFA in 2021, Launch in 1H2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
PK Data for DARE-HRT1 Validates Tech, Supporting Our PT Increase to $11
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Positive DARE-HR-1 Phase 1 Validates IVR Technology for Vaginal Hormone Delivery; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Hormone Replacement Therapy (HRT), Too
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Virtual Marketing by Analyst Zegbeh Jallah Begins @ 12pm ET Tomorrow
Provider: Roth Capital Partners, Inc.
Analyst: Research Department